PMID- 36514664
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 11
DP  - 2022 Nov
TI  - The Association Between Serum Homocysteine Levels and Placenta-Mediated 
      Complications: A Narrative Review.
PG  - e31305
LID - 10.7759/cureus.31305 [doi]
LID - e31305
AB  - The most extremely unfavourable outcome of pregnancy is the death of the mother 
      and newborn. Negative outcomes for mothers or babies can occur as a result of 
      complications or issues during pregnancy, birth or the post-partum period. Early 
      elevated maternal homocysteine (Hct) levels during pregnancy have been linked to 
      altered placental development. There is evidence that suggests an elevated 
      maternal blood Hct level is the new obstetrical risk factor, and the association 
      between hyperhomocysteinemia (HHct) and numerous obstetrical problems was 
      recently recognised. Hct is an essential amino acid, which contains sulphur and 
      is formed from the metabolism of methionine. HHct has several known aetiologies, 
      including genetic anomalies; a deficiency in folic acid, vitamin B6 and vitamin 
      B12; hypothyroidism; old age; and renal illnesses. Vascular problems, coronary 
      artery disease, atherosclerosis and embolic illnesses can all occur as a result 
      of high blood levels of Hct. Hct levels are lower in normal pregnancies than it 
      is in women who are not pregnant. Many pregnancy-related problems, including 
      pre-eclampsia (PE), recurrent pregnancy loss (RPL), placental abruption, 
      premature delivery and foetal growth restriction (FGR) have been connected to 
      HHct in recent research. We looked for pertinent literature using a thorough and 
      systematic search from PubMed, Medline, Embase, Cochrane Library, Google, etc., 
      and articles that were published before August 2022 based on serum Hct levels and 
      various placenta-mediated complications for this review. In this review, we 
      described the synthesis and metabolism of Hct in humans, Hct levels at various 
      phases of normal pregnancy and the association between Hct and placenta-mediated 
      pregnancy complications. The outcomes discovered can help obstetricians increase 
      the likelihood of a successful pregnancy in cases where placenta-mediated issues 
      are present. Lowering Hct levels with a high dose of folic acid tablets during 
      the subsequent pregnancy may be useful for women who experienced these 
      difficulties in prior pregnancies as a result of HHct.
CI  - Copyright (c) 2022, Memon et al.
FAU - Memon, Sharmeen I
AU  - Memon SI
AD  - Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta 
      Meghe Institute of Medical Sciences, Wardha, IND.
FAU - Acharya, Neema S
AU  - Acharya NS
AD  - Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta 
      Meghe Institute of Medical Sciences, Wardha, IND.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221109
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9733802
OTO - NOTNLM
OT  - fetal growth restriction
OT  - homocysteine
OT  - hyperhomocysteinemia
OT  - placenta-mediated complications
OT  - pre-eclampsia
OT  - recurrent pregnancy loss
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/12/15 06:00
MHDA- 2022/12/15 06:01
PMCR- 2022/11/09
CRDT- 2022/12/14 01:58
PHST- 2022/09/25 00:00 [received]
PHST- 2022/11/09 00:00 [accepted]
PHST- 2022/12/14 01:58 [entrez]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/15 06:01 [medline]
PHST- 2022/11/09 00:00 [pmc-release]
AID - 10.7759/cureus.31305 [doi]
PST - epublish
SO  - Cureus. 2022 Nov 9;14(11):e31305. doi: 10.7759/cureus.31305. eCollection 2022 
      Nov.